1M6MYTD1A5AMAX
Cargando cotizaciones...
Previsión
| Comprar |
0 |
| Mantener |
1 |
| Vender |
0 |
Noticias Ir al feed de noticias
Predictive Oncology approves increase to equity incentive plan and issuance of pre‑funded warrants
At the annual meeting, shareholders voted to increase the 2024 Equity Incentive Plan by 1,000,000 shares and to issue 14,903,393 common shares that will be issued upon exercise of pre‑funded warrants. The elections of directors Daniel E. Handley and Chuck Nuzum were confirmed and KPMG was appointed as independent auditors. Predictive Oncology also reported a significant net loss in Q3 2025, but said it has regained compliance with NASDAQ’s minimum stockholders’ equity requirement and is pursuing initiatives to enter the AI infrastructure market. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | jun 2026 | |
|---|---|---|
| Ingresos | 2,82 M | 123.699,49 % |
| Beneficio bruto | 176,69 mil | 1440,23 % |
| Beneficio neto | -15,08 M | 758,24 % |
| EBITDA | -3,52 M | 129,57 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 103,67 M € |
Número de acciones | 11,49 M |
Máximo/mínimo de 52 semanas | 27,71 € - 0,89 € |
| Dividendos | No |
Beta | 3,47 |
Ratio P/E | -0,07 |
Ratio PEG | 0,00 |
Ratio P/B | 6,04 |
Ratio P/S | 36,82 |
Perfil de la empresa
| Nombre | Predictive Oncology |
| CEO | Christopher Miglino |
| Empleados | 14 |
Descubrir activos
Los accionistas de Predictive Oncology también invierten en los siguientes activos
